ArticleAntimicrobial agents and chemotherapy2005
In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.The Journal of dermatology · 2018Trial
- A Rare Case ofJournal of fungi (Basel, Switzerland) · 2025Article
- An update on the development of novel antifungal agents for eumycetoma.Frontiers in pharmacology · 2023Review
- Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.PLoS neglected tropical diseases · 2022Article
- Article
- Article
- The Molecular Identification and Antifungal Susceptibilities of Aspergillus Species Causing Otomycosis in Tochigi, Japan.Mycopathologia · 2019Article
- Pulmonary Scedosporium apiospermum Infection with Pulmonary Tumorlet in an Immunocompetent Patient.Internal medicine (Tokyo, Japan) · 2018Article
- In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.Antimicrobial agents and chemotherapy · 2015Article
- Molecular identification and susceptibility of clinically relevant Scedosporium spp. in China.BioMed research international · 2015Article
- Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.Drugs · 2014Review
- Madurella mycetomatis is highly susceptible to ravuconazole.PLoS neglected tropical diseases · 2014Article
- Melanized fungi in human disease.Clinical microbiology reviews · 2010Review
- Pharmacokinetic/pharmacodynamic profile of posaconazole.Clinical pharmacokinetics · 2010Review
- In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans.Antimicrobial agents and chemotherapy · 2008Article
- Infections caused by Scedosporium spp.Clinical microbiology reviews · 2008Review
- Fusarium infections in immunocompromised patients.Clinical microbiology reviews · 2007Review
- In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.Antimicrobial agents and chemotherapy · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro activities of ravuconazole against 575 clinical strains of Aspergillus spp. and 348 nondermatophyte non-Aspergillus spp. were analyzed. Ravuconazole was active against Aspergillus spp., other hyaline filamentous fungi, black molds, and some Mucorales. Species such as Scedosporium prolificans, Fusarium spp., and Scopulariopsis spp. were resistant to the triazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.